Publications

Browse the library of publications below for the latest research from ADC Therapeutics scientists.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia Jain N, et al. Blood Adv. Feb 2020.

View Publication

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy Thapa B, et al. Blood Adv. Aug 2020.

View Publication

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Hamadani M, et al. Blood. May 2021.

View Publication

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021.

View publication

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study Hamadani M, et al. Lancet Haematol. May 2021.

View publication

Contact ADC Therapeutics

Submit a Medical Inquiry Reach out to the ADC Therapeutics team with your specific medical inquiry.

Contact Medical Affairs 1-855-690-0340
8:00 AM to 6:00 PM ET

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.